ReviewBone marrow transplantation2005
Comorbidity indices in hematopoietic stem cell transplantation: a new report card.
Review in Bone marrow transplantation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Patient anxiety and concern as predictors for the perceived quality of treatment and patient reported outcome (PRO) in orthopaedic surgery.BMC health services research · 2012Article
- Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010Article
- A modified comorbidity index for hematopoietic cell transplantation.Bone marrow transplantation · 2010Article
- Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Article
- Non-myeloablative allogeneic hematopoietic stem cell transplantation.Seminars in oncology nursing · 2009Review
- Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009Article
- Impact of comorbidity indexes on non-relapse mortality.Leukemia · 2008Article
- Assessing the risk of transplant-related complications and individually tailoring the HSCT procedure in children and adolescents--is it possible?Bone marrow transplantation · 2008Review
- Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?Bone marrow transplantation · 2006Review
- Review
- Transfer of the hematopoietic stem cell transplant patient to the intensive care unit: does it really matter?Bone marrow transplantation · 2006Review
- Comorbidity and beyond: pre-transplant clinical assessment.Bone marrow transplantation · 2005Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT). Patients formerly excluded from myeloablative transplant due to comorbid illnesses now receive reduced-intensity conditioning regimens; hence, the incidence of comorbid conditions in HSCT recipients is expected to increase. Comorbid grading systems developed without regard for oncology patients have been applied in retrospective fashion to HSCT patients. Two commonly used scales (Charlson Comorbidity Index and the Adult Comorbidity Inventory-27) fail to include critical information: tumor and histologic type/stage, extent of prior treatment, donor stem cell source and cell type and preparative regimen. Further, data are reported in retrospective rather than prospective fashion. Despite limitations, however, such grading systems exhibit ease and utility for evaluation and may have predictive value for patient outcome. Modifying such approaches to include additional factors and appropriate weighting of components may enable an improved comparison of techniques and study results. These scoring systems may elucidate predictors of outcome and disease natural history and enhance statistical efficiency methods of HSCT. Refined scoring could be used effectively to assign patients to differing transplant conditioning regimens, that is, myeloablative vs reduced intensity. Prospective validation of such grading systems is encouraged.
Indexed as
Identifiers
15995717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.